[Long-term outcomes of anti-VEGF therapy for macular edema in retinal vein occlusion].

Antiangiogenic therapy (anti-VEGF) is the standard in the treatment of many retinal vascular diseases, including macular edema associated with retinal vein occlusion (RVO). A large evidentiary basis has been collected, consisting of randomized clinical trials in which anti-VEGF therapy demonstrated a significant advantage over laser photocoagulation and placebo in patients with RVO. However, in everyday clinical practice the results are not always comparable to randomized clinical trials. This review presents an analysis of the current studies based on actual clinical practice. Their results helped identify the main aspects of antiangiogenic therapy that could improve the treatment outcomes for patients with RVO. Additionally, the article discusses the predictive factors for therapy outcomes and the effect of anti-VEGF therapy on the development of neovascular complications in patients with ischemic RVO.

• Publication year

  2022

• Venue

  Vestnik oftal mologii

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.17116/oftalma2022138031140PMID 35801893
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study

  2021cited by this paper
• Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry

  2021cited by this paper
• Optical coherence tomographic patterns in patients with retinal vein occlusion and macular edema treated by ranibizumab: a predictive and personalized approach

  2021cited by this paper
• Outcomes of Eyes Lost to Follow-Up in Patients with Central Retinal Vein Occlusion Who are Receiving Anti-Vascular Endothelial Growth Factor Treatment

  2021cited by this paper
• Real-life study of the use of anti-VEGF therapy versus dexamethasone implant for treatment of macular edema in retinal vein occlusion

  2021cited by this paper
• Long-term outcomes of anti-VEGF treatment of retinal vein occlusion

  2021cited by this paper
• Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes

  2020cited by this paper
• Evaluation of the effectiveness of intravitreal administration of a dexamethasone implant in patients with macular edema due to retinal vein occlusion

  2020cited by this paper
• Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser

  2020cited by this paper
• Outcomes in retinal vein occlusions presenting with poor visual acuity treated with anti-VEGF therapy: prognosis and predictive factors.

  2020cited by this paper
• Patient-reported outcomes from a phase IV study of aflibercept in patients with refractory retinal vein occlusions

  2020cited by this paper
• Real-world outcomes with ranibizumab in branch retinal vein occlusion: The prospective, global, LUMINOUS study

  2020cited by this paper
• Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors

  2019cited by this paper
• Loss of Peak Vision in Retinal Vein Occlusion Patients Treated for Macular Edema.

  2019cited by this paper
• INJECTION FREQUENCY OF AFLIBERCEPT VERSUS RANIBIZUMAB IN A TREAT-AND-EXTEND REGIMEN FOR CENTRAL RETINAL VEIN OCCLUSION: A Randomized Clinical Trial.

  2019cited by this paper
• Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA)

  2019cited by this paper
• [Complex assessment of retinal ischemic damage in patients with retinal vein occlusion].

  2019cited by this paper
• Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors

  2019cited by this paper
• Cytokines and the Pathogenesis of Macular Edema in Branch Retinal Vein Occlusion

  2019cited by this paper
• Real-Life Evidence for Using a Treat-and-Extend Injection Regime for Patients with Central Retinal Vein Occlusion

  2019cited by this paper
• Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1‐year results of the COMRADE extension study

  2018cited by this paper
• A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion

  2018cited by this paper
• Impact of Time to Anti-Vascular Endothelial Growth Factor Intervention on Visual Outcomes for Patients Diagnosed With Retinal Vein Occlusion.

  2018cited by this paper
• [Anti-VEGF dosing regimen for neovascular age-related macular degeneration treatment].

  2018cited by this paper
• STUDIES OF SYSTEMIC AND LOCAL CYTOKINE LEVEL IN RETINAL VEIN OCCLUSION ASSOCIATED WITH ANTIANGIOGENIC THERAPY

  2018cited by this paper
• Integrated results from the COPERNICUS and GALILEO studies

  2017cited by this paper
• RANIBIZUMAB FOR RETINAL VEIN OCCLUSION: Predictive Factors and Long-Term Outcomes in Real-Life Data

  2017cited by this paper
• Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseases

  2017cited by this paper
• Anti-VEGF treatment and peripheral retinal nonperfusion in patients with central retinal vein occlusion

  2017cited by this paper
• Reversible retinal vessel closure from VEGF-induced leukocyte plugging.

  2017cited by this paper
• Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.

  2016cited by this paper
• Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion

  2016cited by this paper
• [Foveolar effects of dexamethasone intravitreal implant in central retinal vein occlusion].

  2016cited by this paper
• [Intraocular cytokines imbalance in retinal vein occlusion and its impact on the efficacy of anti-angiogenic therapy].

  2015cited by this paper
• Role of soluble vascular endothelial growth factor receptor signaling and other factors or cytokines in central retinal vein occlusion with macular edema.

  2015cited by this paper
• Prospective Evaluation of Morphological and Functional Changes after Repeated Intravitreal Dexamethasone Implant (Ozurdex®) for Retinal Vein Occlusion

  2015cited by this paper
• A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results

  2015cited by this paper
• RANIBIZUMAB IN PREPROLIFERATIVE (ISCHEMIC) CENTRAL RETINAL VEIN OCCLUSION: The Rubeosis Anti-VEGF (RAVE) Trial

  2014cited by this paper
• Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials.

  2014cited by this paper
• Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study.

  2014cited by this paper
• Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study.

  2014cited by this paper
• Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.

  2014cited by this paper
• Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion.

  2013cited by this paper
• Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6‐month follow‐up – The SOLO study

  2013cited by this paper
• Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.

  2012cited by this paper
• Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

  2012cited by this paper
• Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion

  2010cited by this paper
• Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.

  2010cited by this paper
• The effect of a preoperative subconjuntival injection of dexamethasone on blood–retinal barrier breakdown following scleral buckling retinal detachment surgery: a prospective randomized placebo-controlled double blind clinical trial

  2010cited by this paper
• Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.

  2010cited by this paper
• Neovascular glaucoma.

  2007cited by this paper
• Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6.

  2005cited by this paper

• Effect of Adjuvant Conbercept on Patients with Macular Edema Induced by Diabetic Retinopathy and Retinal Vein Occlusion Undergoing Laser Treatment: Impact on Symptom Improvement

  2025cites this paper